晚期非小细胞肺癌 EGFR敏感突变型患者酪氨酸激酶抑制药的疗效和安全性

 目的 观察晚期非小细胞肺癌表皮生长因子受体(EGFR)敏感突变型患者酪氨酸激酶抑制药(EGFR-tyrosine-kinase inhibitor,EGFR- TKI)的疗效和安全性。方法 32例EGFR敏感突变型晚期非小细胞肺癌患者一线化疗后给予EGFR- TKI维持治疗。观察近期疗效、无进展生存期(progression-free-survival, PFS)、总生存期(overall survival, OS)及不良反应。结果 全组CR 3例,PR 7例,SD 18例,PD 4例。有效率 RR 31.3%,疾病控制率DCR 87.5 %;中位PFS 14.9个月(95% CI:11.93 ~17.87个月);中位OS 25.1个月(95% CI:20.8~29.3个月)。全组无重度不良反应发生,治疗耐受良好。皮疹发生率37.5%,腹泻发生率15.6%。结论 晚期非小细胞肺癌 EGFR敏感突变型患者EGFR- TKI维持治疗安全有效。

EGFR-TKI maintenance therapy for advanced non-small-cell lung cancer with positive EGFR mutation

Objective To investigate the efficacy and safety of EGFR-tyrosine-kinase inhibitor(EGFR-TKI)as maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) and positive EGFR mutation. Methods Thirty-two patients who suffered from advanced NSCLC with EGFR mutation-positive were given EGFR-TKIS (Gefitinib, Taceva or Icotinib) as maintenance therapy following first-line chemotherapy and no disease progression. Clinical efficacy, progression-free survival (PFS), overall survival (OS) and adverse events were analyzed. Results Complete remission(CR), partial remission(PR), stable disease(SD) and progressing disease(PD)were observed in 3, 7, 18 and 4 cases, respectively. Response rate (RR) was 31.3% and disease control rate (DCR) was 87.5% in the group. Median PFS was 14.9 months(95% CI:11.93~17.87) and mOS was 25.1 months (95% CI:20.8~29.3). The most common adverse events were rash (37.5%) and diarrhea (15.6%). Conclusions EGFR-TKIs as maintenance therapy in the patients with advanced NSCLC and EGFR mutation-positive is effective and safe.